Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
Administration, Intravenous
Adult
Aged
Coordination Complexes
Female
Humans
Injections, Intra-Arterial
Liver Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Grading
Neuroendocrine Tumors
/ diagnostic imaging
Octreotide
/ administration & dosage
Organometallic Compounds
/ administration & dosage
Pilot Projects
Prospective Studies
Radiopharmaceuticals
/ administration & dosage
Radiotherapy Dosage
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
pubmed:
7
8
2021
medline:
28
9
2021
entrez:
6
8
2021
Statut:
ppublish
Résumé
The aim of the present study was to perform calculation of the absorbed doses to organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (IA) injection of 29 patients with Grade I-II, inoperable, metastatic gastro-entero-pancreatic neuroendocrine tumor (GEPNET) were prospectively identified and enrolled for the study. 15 patients of GEPNETs with liver-dominant metastatic disease and less than 3 sites of extrahepatic metastatic disease were administered a single dose of The mean dose per unit activity (DpA) in the liver and tumor lesions in the IA group differed significantly ( IA administration of Measurement of the dose received by the tumor lesions and the critical organs is of paramount importance for the prognostication of a radionuclide therapy. Scant data exist on the dosimetric impact of IA administration of the therapy with
Identifiants
pubmed: 34357794
doi: 10.1259/bjr.20210403
pmc: PMC9328058
doi:
Substances chimiques
177Lu-DOTA-octreotate
0
Coordination Complexes
0
Organometallic Compounds
0
Radiopharmaceuticals
0
lutetium Lu 177 dotatate
AE221IM3BB
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20210403Références
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1480-1489
pubmed: 28331954
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382
pubmed: 32123969
J Nucl Med. 2006 Sep;47(9):1476-82
pubmed: 16954556
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500
pubmed: 28361189
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
Cancer Biother Radiopharm. 2014 May;29(4):179-87
pubmed: 24820805
Cancer Biother Radiopharm. 2005 Apr;20(2):215-7
pubmed: 15869458
Appl Radiat Isot. 2007 Mar;65(3):301-8
pubmed: 17110119
Endocr Relat Cancer. 2011 Sep 20;18(5):595-602
pubmed: 21791571
Q J Nucl Med Mol Imaging. 2012 Dec;56(6):551-8
pubmed: 23358409
Eur J Nucl Med. 1999 Jul;26(7):693-8
pubmed: 10398816
Clin Cancer Res. 2010 May 15;16(10):2899-905
pubmed: 20460485
Trials. 2020 Feb 5;21(1):141
pubmed: 32024533
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Br J Radiol. 2018 Nov;91(1091):20170172
pubmed: 30028180
J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S
pubmed: 15653657
Eur J Nucl Med. 2001 Dec;28(12):1743-50
pubmed: 11734910